Teva: 'Celltrion deal will double biosimilar sales to $600m'
Celltrion presents Truxima's results of phase 3 clinical trials in US forum
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire
Teva confident in September approval for migraine drug despite latest Celltrion plant citation | Fierce Pharma
Biosimilars: Celltrion paves way for Herceptin copycats in 2018 - Pharmaceutical Technology
Teva, Celltrion win FDA approval for Rituxan biosimilar - Globes
Teva and Celltrion Launch Trastuzumab Biosimilar in U.S. - Big Molecule Watch
Celltrion launches Herceptin biosimilar in US
Celltrion, Teva announce FDA approval of HERZUMA
Teva, Celltrion get FDA nod for biosimilar to Roche's cancer drug Rituxan
Celltrion and Teva Snag Second Biosimilar Approval of a Genentech Drug | BioSpace
Teva teams up on biosims with Celltrion three years after its Lonza JV divorce | Fierce Biotech
Teva and Celltrion Launch Herzuma (biosimilar- trastuzumab) in the US
Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. | Fierce Pharma
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership | World Pharma Today
Celltrion signs $160m drug license deal with Teva for North America - Nikkei Asia
Jobs with Celltrion Healthcare (Formerly Known As Celltrion) | page 2
Teva bolsters its biosimilar business through $160m Celltrion deal
Teva and Celltrion Launch Rituximab Biosimilar in US - Big Molecule Watch
Celltrion's Q3 earnings beat market consensus to hit record high - KED Global
New data raise profile of Truxima at EHA 2021
Celltrion says COVID-19 antibody kills virus within 5 days; shares surge - KED Global
